Aspen Neuroscience (ASPE) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics is the larger company by market cap ($385.7 million vs $361.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASPE | IRD |
|---|---|---|
| Share price | $12.42 | $3.99 |
| Market cap | $361.16M | $385.65M |
| 1-day change | +0.24% | -2.21% |
| YTD return | — | +98.51% |
| 1-year return | — | +108.90% |
| 5-year return | — | -8.28% |
| EPS (TTM) | $-4.89 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $14.20M |
| Revenue growth (YoY) | — | +29.15% |
| Net income (latest FY) | — | $-49.59M |
| Operating margin | — | -271.90% |
| Net margin | — | -349.33% |
| 52-week high | $14.90 | $7.07 |
| 52-week low | $11.20 | $1.88 |
| Distance from 52-week high | -16.64% | -43.56% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +249.37% |
| Average volume | 352.42K | 2.56M |
| Shares outstanding | 29.08M | 96.65M |
| Employees | 120 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aspen Neuroscience
ASPE stock →Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
ASPE vs IRD FAQ
Which is bigger, Aspen Neuroscience or Opus Genetics?
Opus Genetics (IRD) is larger, with a market capitalization of $385.65M compared with $361.16M for Aspen Neuroscience (ASPE).
Are Aspen Neuroscience and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.